| Literature DB >> 14554157 |
Abstract
Inactivated vaccines require adjuvants to stimulate an immune response. The choice of adjuvant or immune enhancer determines whether the immune response is effective, ineffective or damaging. Accordingly, there is a need for new adjuvants that stimulate the appropriate immunity, for example, T cell immunity for intracellular pathogens and cancer vaccines. In several adjuvants, the identification of chemical groups that interact with specific cell toll-like receptors (innate immunity) or receptors for co-stimulatory ligands (adaptive immunity), has enabled the establishment of structure-function relationships that are useful in the design of new adjuvants. Because of the crucial immunomodulating role of adjuvants, sub-unit vaccine development will remain dependent on new adjuvants.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14554157 DOI: 10.1016/s1359-6446(03)02864-2
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851